Clinical Trial

A RCT on the Preventive Effect of HFNC on Postoperative Pulmonary Complications in Patients With Gynecologic Neoplasms

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 23, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Patients at high risk of post-operative pulmonary complications (PPC) will be screened out from gynecological tumor patients undergoing surgical treatment, and randomly assigned into the HFNC group and control group, which uses conventional nasal cannula oxygen therapy. The primary outcome is the incidence of PPC, including postoperative hypoxemia, atelectasis, pneumonia, etc. Secondary outcomes are the improvement of postoperative oxygenation, antibiotic use, length of hospital stay, adverse events related to oxygen therapy, etc.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-09-01; most recent amendment 2025-05-20.
Status change: Not Yet Recruiting → Recruiting 2023-08-10
Trial Details
NCT Number NCT05526534
Lead Sponsor Sichuan Cancer Hospital and Research Institute
Conditions Gynecologic Surgery, High-flow Nasal Cannula, Post-operative Pulmonary Complications
Enrollment 200 participants
Start Date 2022-11-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-23